Is there any other way to treat resistance to nilotinib after taking chronic pills?

When patients with chronic myelogenous leukemia (CML) develop resistance to nilotinib, several strategies can be adopted.

Physicians may consider increasing the dose of nilotinib to see if efficacy can be regained. But this method needs to be carried out under close supervision by doctors to ensure patient safety. If increasing the dose is ineffective or not feasible, your doctor may consider switching to another tyrosine kinase inhibitor, such as dasatinib or boletinib. These drugs are also effective options for treating CML and may result in better outcomes for patients.

The combined use of other drugs, such as third-generation tyrosine kinase inhibitors (such as apotinib) and nucleoside analogs, can interfere with the expression of the BCR-ABL gene, thereby improving the therapeutic effect. This combination regimen may help overcome resistance to nilotinib.

RNAInterference technology can also be used to enhance the efficacy of nilotinib or other drugs by inhibiting the expression of specific resistance genes. This approach offers new possibilities for personalized treatment.

CAR-TCell therapy is an emerging immunotherapy method that modifies a patient's T cells to recognize and attack cancer cells. This approach has shown effectiveness against certain cancers in clinical trials and may play an important role in chronic neutrophil therapy.

Epigenetic regulation studies epigenetic changes in cells and develops new drugs to reverse the development of drug resistance. This is a cutting-edge research area that may provide new ideas for future chronic pellet therapy.

For some patients with highly drug-resistant or worsening disease, allogeneic hematopoietic stem cell transplantation may be an effective option. This method can rebuild the patient's hematopoietic system, making it possible to cure CML. However, the risks and costs of transplantation are relatively high and need to be considered on a patient-specific basis.